Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload

Gene

Volumn 543, Issue 1, 2014, Pages 161-165

  Sun, Li ^a,b   Guo, Wenli ^b   Yin, Chunyang ^b   Zhang, Shuping ^b   Qu, Guangbo ^b   Hou, Yanli ^a   Rong, Haiqin ^a   Ji, Hong ^a   Liu, Sijin ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b RESEARCH CENTER FOR ECO ENVIRONMENTAL SCIENCES   (China)

Author keywords

Bone resorption; Bone strength; Hepcidin deficiency; Iron overload

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; HEPCIDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE METABOLISM; BONE STRENGTH; BONE STRESS; CONTROLLED STUDY; IRON OVERLOAD; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; WEIGHT BEARING;

MUS;

BONE RESORPTION; BONE STRENGTH; HEPCIDIN DEFICIENCY; IRON OVERLOAD;

ANIMALS; BONE AND BONES; BONE RESORPTION; HEPCIDINS; HOMEOSTASIS; IRON; IRON OVERLOAD; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOGENESIS; WEIGHT-BEARING;

EID: 84899649150     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.02.023     Document Type: Article

References (70)

1. Adams-Graves P., Daniels A.B., Womack C.R., Freire A.X. Bone mineral density patterns in vitamin D deficient African American men with sickle cell disease. Am. J. Med. Sci 2013, 10.1097/MAJ.0b013e3182893377.
2. Alexandre C. Diagnosis and treatment of osteoporosis. Curr. Opin. Rheumatol. 1995, 7:240-242.
3. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112:219-230.
4. Brissot P., Bardou-Jacquet E., Jouanolle A.M., Loreal O. Iron disorders of genetic origin: a changing world. Trends Mol. Med. 2011, 17:707-713.
5. Chevalley T., et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos. Int. 1994, 4:245-252.
6. Christenson E.S., Jiang X., Kagan R., Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol. 2012, 64:181-194.
7. Cooper C., Aihie A. Osteoporosis. Baillieres Clin. Rheumatol. 1995, 9:555-564.
8. Cross A.J., et al. Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prev. Res. (Phila.) 2011, 4:1465-1475.
9. Delbarre F. Osteoarticular manifestations of hemochromatosis. Presse Med. 1964, 72:2973-2978.
10. Di Marco V., et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008, 93:1243-1246.
11. Diamond T., Stiel D., Lunzer M., Wilkinson M., Roche J., Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990, 31:82-87.
12. Fiore C.E., Malatino L.S., Tamburino G. Bone Gla-protein (osteocalcin): a new metabolic marker of calcified tissues. Recenti Prog. Med. 1984, 75:361-381.
13. Fleming R.E., Sly W.S. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu. Rev. Physiol. 2002, 64:663-680.
14. Fohr B., Dunstan C.R., Seibel M.J. Clinical review 165: markers of bone remodeling in metastatic bone disease. J. Clin. Endocrinol. Metab. 2003, 88:5059-5075.
15. Fridovich I. The biology of oxygen radicals. Science 1978, 201:875-880.
16. Galaris D., Pantopoulos K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit. Rev. Clin. Lab. Sci. 2008, 45:1-23.
17. Gama R., Smith M.J., Wright J., Marks V. Hypopituitarism in primary haemochromatosis; recovery after iron depletion. Postgrad. Med. J. 1995, 71:297-298.
18. Ganz T. Hepcidin and iron regulation, 10years later. Blood 2011, 117:4425-4433.
19. Ganz T., Olbina G., Girelli D., Nemeth E., Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112:4292-4297.
20. Guggenbuhl P., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos. Int. 2005, 16:1809-1814.
21. Guggenbuhl P., Brissot P., Loreal O. Miscellaneous non-inflammatory musculoskeletal conditions. Haemochromatosis: the bone and the joint. Best Pract. Res. Clin. Rheumatol. 2011, 25:649-664.
22. Guggenbuhl P., et al. Bone status in a mouse model of genetic hemochromatosis. Osteoporos. Int. 2011, 22:2313-2319.
23. Haidar R., Musallam K.M., Taher A.T. Bone disease and skeletal complications in patients with beta thalassemia major. Bone 2011, 48:425-432.
24. Halliwell B., Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990, 186:1-85.
25. Hauschka P.V., Carr S.A. Calcium-dependent alpha-helical structure in osteocalcin. Biochemistry 1982, 21:2538-2547.
26. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
27. Ishii K.A., et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat. Med. 2009, 15:259-266.
28. Jelic M., et al. Hepcidin and iron metabolism disorders in patients with chronic kidney disease. Vojnosanit. Pregl. 2013, 70:368-373.
29. Jia P., et al. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J. Orthop. Res. 2012, 30:1843-1852.
30. Jian J., Pelle E., Huang X. Iron and menopause: does increased iron affect the health of postmenopausal women?. Antioxid. Redox Signal. 2009, 11:2939-2943.
31. Jin P., et al. Study on abnormal iron metabolism and iron overload in patients with aplastic anemia. Zhonghua Xue Ye Xue Za Zhi 2013, 34:877-882.
32. Juanola-Falgarona M., et al. Association between serum ferritin and osteocalcin as a potential mechanism explaining the iron-induced insulin resistance. PLoS One 2013, 8:e76433.
33. Kamai T., Tomosugi N., Abe H., Arai K., Yoshida K.-I. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 2009, 9:270.
34. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos. Int. 1994, 4:368-381.
35. Knutson M.D. Iron-Sensing proteins that regulate hepcidin and enteric iron absorption. Annu. Rev. Nutr. 2010, 30:149-171.
36. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127:S79-S86.
37. Kudo H., Suzuki S., Watanabe A., Kikuchi H., Sassa S., Sakamoto S. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology 2008, 246:143-147.
38. Lesbordes-Brion J.C., et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006, 108:1402-1405.
39. Li G.F., Pan Y.Z., Sirois P., Li K., Xu Y.J. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos. Int. 2012, 23:2403-2408.
40. Lian J.B., Gundberg C.M. Osteocalcin. Biochemical considerations and clinical applications. Clin. Orthop. Relat. Res. 1988, 267-91.
41. Lian J.B., Roufosse A.H., Reit B., Glimcher M.J. Concentrations of osteocalcin and phosphoprotein as a function of mineral content and age in cortical bone. Calcif. Tissue Int. 1982, 34(Suppl. 2):S82-S87.
42. Lin H., Lian W.S., Chen H.H., Lai P.F., Cheng C.F. Adiponectin ameliorates iron-overload cardiomyopathy through the PPARalpha-PGC-1-dependent signaling pathway. Mol. Pharmacol. 2013, 84:275-285.
43. Liu S., et al. The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation. J. Clin. Invest. 2007, 117:3296-3305.
44. - mice. Haematologica 2008, 93:753-756.
45. Lopez-Escribano H., et al. Effect of co-inheritance of beta-thalassemia and hemochromatosis mutations on iron overload. Hemoglobin 2012, 36:85-92.
46. Lorincz G., Traub N.E., Chuke P.O., Hussain S.F. African haemosiderosis associated with osteoporosis and vertebral collapse. East Afr. Med. J. 1974, 51:488-495.
47. Maes K., et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010, 116:3635-3644.
48. Masaratana P., Laftah A.H., Latunde-Dada G.O., Vaulont S., Simpson R.J., McKie A.T. Iron absorption in hepcidin1 knockout mice. Br. J. Nutr. 2011, 105:1583-1591.
49. Mattila P., Knuuttila M., Kovanen V., Svanberg M. Improved bone biomechanical properties in rats after oral xylitol administration. Calcif. Tissue Int. 1999, 64:340-344.
50. Mizuno A., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247:610-615.
51. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009, 122:78-86.
52. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276:7806-7810.
53. Pinnix Z.K., et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2010, 2:43ra56.
54. Ramos E., et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012, 120:3829-3836.
55. Reginster J.Y., et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif. Tissue Int. 2001, 69:130-137.
56. Rong H. Excess iron undermined bone load-bearing capacity through tumor necrosis factor-α-dependent osteoclastic activation in mice. Biomed. Rep. 2012, 1:85-88.
57. Salama O.S., Al-Tonbary Y.A., Shahin R.A., Eldeen O.A. Unbalanced bone turnover in children with beta-thalassemia. Hematology 2006, 11:197-202.
58. -) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013, 121:1200-1208.
59. Song S.N., et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther. 2013, 15:R141.
60. Steinbicker A.U., et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011, 118:4224-4230.
61. Stevens R.G., Jones D.Y., Micozzi M.S., Taylor P.R. Body iron stores and the risk of cancer. N. Engl. J. Med. 1988, 319:1047-1052.
62. Suda T., Udagawa N., Takahashi N. Cells of Bone: Osteoclast Generation 1996, Academic Press, San Diego.
63. Szalay F. Hemochromatosis: one form of iron-overload diseases. Orv. Hetil. 2013, 154:1156-1164.
64. Tanno T., et al. Hepcidin, anaemia, and prostate cancer. BJU Int. 2011, 107:678-679.
65. Tsay J., et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 2010, 116:2582-2589.
66. Valenti L., Varenna M., Fracanzani A.L., Rossi V., Fargion S., Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos. Int. 2009, 20:549-555.
67. Wu T., Sempos C.T., Freudenheim J.L., Muti P., Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann. Epidemiol. 2004, 14:195-201.
68. Wu X., et al. Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS One 2012, 7:e44622.
69. Yamasaki K., Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol. Lett. 2009, 191:211-215.
70. Zhang W., et al. Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol. Neurobiol 2013, 10.1007/s12035-013-8586-4.